Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UGXGL
ADC Name
hu08-Malpeg-3906
Synonyms
hu08 Malpeg-3906
   Click to Show/Hide
Organization
Pfizer Inc.
Drug Status
Investigative
Drug-to-Antibody Ratio
4.3
Antibody Name
IL13Ralpha2-AB08-v1.0/1.2
  Antibody Info 
Antigen Name
Interleukin-13 (IL13)
  Antigen Info 
Payload Name
hu08-Malpeg-3906 payload
  Payload Info 
Linker Name
hu08-Malpeg-3906 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 31.1
%
CVCL_4885
Prostate carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 31.10% Positive IL13 expression (IL13+++/++)
Method Description
Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model PC3-MM2 CDX model
In Vitro Model Prostate carcinoma PC3-MM2 cells CVCL_4885
References
Ref 1 Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates.